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Introduction and aim of the thesis 
Statistical analysis of cancer mortality in Europe revealed a poor result for the 
Hungarian population. In male population, Hungary is the leader of cancer mortality and third 
among females. Considering the upper respiratory tract the mouth, pharyngeal (16.5/100000), 
laryngeal (9.2/100000) cancer is the leading cause of death and Hungarian women also 
display high mortality in pharyngeal (2.1/100000) and laryngeal cancer (0.7/100000) (Levy F. 
et al., 1995). This high rate of cancer mortality is associated with habits of drinking, smoking 
and nutrition so it is related to social problems. Prevention of the disease is until now 
insufficient. 
So that head and neck oncology concentrates on the early detection of tumor utilizing 
diagnostic methods that contribute to the detection of tumor at an early stage and better 
evaluation of size, location and extension of the cancer. Endoscopy, sonography, computer 
tomography (CT), magnetic resonance imaging (MRI) give important additional information 
to the routine clinical examination. More sensitive procedure for finding tumor cells at 
molecular level could be the detection of tumor markers (III, XIII.). These were also 
introduced in our clinical practice to detect tumor antigens in serum and for monitoring the 
disease, nevertheless these methods revealed low sensitivity and less specific markers for 
head and neck tumors (IE.). 
Treatment of the laryngeal and hypopharyngeal tumors consists of generally accepted 
methods: surgery, radiation therapy and chemotherapy. At the Department of 
Otorhinolaryngology, Head and Neck Surgery, University of Szeged surgical intervention is 
the primary treatment of choice for most of these cancers with additional radiation and/or 
chemotherapy. 
Surgery has developed in the last decades introducing new techniques in 
otorhinolaryngology like external partial laryngectomies and endolaryngeal endoscopic 
surgery preserving laryngeal functions resulting in a better postoperative quality of life. 
Endoscopic CO2 laser excision has brought a new modality to the surgical procedures 
in the laryngology. In the 80', endoscopic CO2 surgery has gained acceptance only for Tla 
vocal cord tumor versus external surgery in the literature. Some otorhinolaryngological 
centers (Göttingen, Kiel) reported extended use of CO2 laser but there was no agreement on 
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the possible extension of laser excision in laryngeal tumors. In our clinic we tried to apply 
laser excision for early cancer of the vocal cord and later on we extended the method for 
supraglottis and marginal tumors searching for the borderline of this endoscopic technique in 
the management of laryngeal tumors. We have planned a study to evaluate how endoscopic 
CO2 laser technique is applicable for benign tumors (II.) and malignancies focusing on vocal 
cord and supraglottic tumors. Another aim was to present the limitations of this minimally 
invasive endoscopic method and safety of the resection-margins of TI, T2 cancers from 
oncological aspect as a curative treatment. 
1. Aim of the endoscopic CO ¿laser study (I. Chapter): 
At the Department of Otorhinolarynglology, Head and Neck Surgery endoscopic CO2 
laser excision of vocal cord tumor was introduced by Professor Jenő Czigner in 1987 and later 
in the nineties we started to apply this endoscopic technique for selected supraglottic cancers 
and exceptionally for T1 hypopharyngeal cancers. 
Here I would like to present our results on the laser excision of glottic cancer and the 
later introduced extended endoscopic excision of the supraglottic cancer in our clinic. 
Nevertheless, advantages of endoscopic removal of tumor are also presented resulting in a 
better quality of life (QOL). 
Surgical techniques, radiation- and chemotherapy for cancer have reached the limits of 
their abilities as curative treatments and the survival of treated patients has not changed 
significantly lately. Research has shifted to search for causative therapy at molecular, genetic 
and immune response level. By these ways research activities has brought new additional 
therapies - including immunotherapy - fighting for improvement of survival rate in the future. 
Immunotherapy represents many methods of cancer treatment at molecular and 
antibody level targeting tumor cells by activating the immune system. 
Tumor cells can be reached and targeted by activated immune cells using active 
immunotherapy (gene therapy, vaccination) and passive immunotherapy (monoclonal 
antibody, bispecific antibody). 
The use of bispecific antibodies became a promising tool for the activation of immune 
cells destroying tumor cells versus monoclonal antibody. Bispecific antibodies (VIII., IX.) 
have the chance - because of the different Fab and intact Fc region of the antibody - to 
3 
redirect each classes of inactivated immune cells, including T cells and accessory cells, which 
is inevitable to the full immune response. A new class of intact bispecific antibody (BiuII) 
was produced and used at the University of Munich, Grosshadern, Germany and I had the 
chance to work in this research-team. 
2. Aim of the study with biscpecific antibody - BiUII (II. Chapter): Effects of the 
bispecific antibody on immune cells and tumor lysis in cell lines. 
We aimed to study the tumor lysis capacity of bispecific antibody (BiUII) in cell lines 
and investigated its binding to the pancarcinoma antigen (Ep-CAM,-epithelial cell adhesion 
molecule-) - generally expressed on human head and neck tumors -, CD3 antigen of T cell 
and accessory cells. 
We also studied the contribution of this bispecific antibody with an intact Fc-region (Fcy-
receptor) to the complex immune response that can result in full activation of all class of 
immune cells attracting accessory cells, too. 
At the University of Munich we investigated the in vitro function of accessory cells 
like monocytes/macrophages in the immunosuppressive surrounding of tumor cell lines to 
give evidence for inactivation of monocytes and by this way deterioration of the immune 
response. 
3. Aim of the tumor immunological study (HI. Chapter): We decided to answer the 
question, how PGE2 produced by tumor cells creates an immunosuppressive condition 
modifying receptors on the surface of monocytes. These receptors, like chemokine receptors -
CCR5 and Mac-1 - have a major role in chemotaxis and migration of these effector cells from 
blood vessels and direction of immune cells to eliminate tumor cells. Therefore migration and 
chemotaxis assay was designed and evaluated. Effects of non-steroid anti-inflammatory drugs 
(NSAIDS) like aspirin or indomethacin on the inhibited migratory and chemotactic potential 
of accessory cells (peripheral blood monocytes) were examined. We tried to give a 
therapeutical modality to regain the activation of immune cells in vitro and it would have also 
therapeutical consequences for cancer patients, too. 
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I. Chapter - Surgical therapy: 
Minimally invasive, endolaryngeal C02 laser for cancer of the larynx 
1.1. Background of endoscopic CO2 laser surgery 
Treatment of early glottic and supraglottic cancer is divided into radiation therapy, 
surgery and chemotherapy. In the English speaking countries radiation therapy has been long 
applied and has now great experience with this technique. Kleinsasser first introduced 
endoscopic surgical technique for laryngeal and hypopharygeal tumor in the 60's. 
After the development of endoscopic surgery utilization of CO2 laser excision has 
gained acceptance in some otorhinolaryngological centers versus radiation therapy. 
Advantages of this minimally invasive surgical technique versus radiation therapy have been 
shown and published in comparative studies. 
Minimally invasive, endoscopic CO2 laser intervention became an applicable method 
as conservation surgery for early glottic cancer but later carefully selected patients with 
supraglottic laryngeal carcinoma were also treated by this method in our clinic, too. 
Laser resection of early glottic cancer results in as good or even better survival than 
radiation therapy in the literature. 
For selected cases of early supraglottic cancer endolaryngeal CO2 laser can be also a 
treatment of choice instead of external approach surgical intervention. 
Laser surgery is indicated predominantly for T1 cancer like vocal cord cancer or tumor 
of the epiglottis, but T2 tumors can be also resected by this method. For more advanced 
tumors (T2, T3, T4) external approach surgery remained the standard treatment modality in 
the future (partial or total laryngectomy) but Rudert (1995) and Steiner (1991) reported 
extended use of laser for advanced laryngeal and hypopharyngeal tumors, too. 
1.2 Introduction 
Minimally invasive, endolaryngeal surgical technique for early stage laryngeal tumors 
applying CO2 laser became a treatment of choice in the surgery of larynx (1, 2). It has been 
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introduced into the clinical practice in the beginning of eighties in some 
otorhinolaryngological centers in Europe and in 1987 at the Department of 
Otorhinolaryngology, University of Szeged. 
Endolaryngeal CO2 laser excision of Tla, Tib carcinomas of the vocal cord became 
accepted as an adequate surgical intervention (1, 2, 4, 11) in our clinic. This modality for the 
removal of the vocal cord tumor has proved to be more effective than external surgery or 
radiation therapy (1, 3-6). An experienced oncologist (7-9) must establish the indication. 
Laser excision allows minimally invasive therapy at an early stage (TI, T2) but has also been 
reported in the laser therapy for T3 glottic cancer (9-12). Endoscopic removal of T3 laryngeal 
tumor is controversial. 
Steiner (24), Rudert and Werner (22, 23) reported their indications for transoral CO2 
laser excisions of supraglottic and hypopharyngeal tumors after careful patient selection. 
Although their reports represented the surgeon's experience, the better majority of extensive 
laryngeal and hypopharyngeal carcinomas were found to be resected by external partial 
laryngectomies and partial pharyngectomies. Davis et al. (17, 18) reported that curative CO2 
laser excisions were a good option only in selected early supraglottic cancer patients. This 
method was satisfactory in tumors of the suprahyoid epiglottis, but the possible infiltration of 
the pre-epiglottic space by infrahyoid epiglottic tumors was indicative for open surgery. 
Adjuvant radiation therapy was also recommended after resection of an infrahyoid tumor 
(20). However, laser excision can be used for epiglottectomy even after radiation therapy and 
the method is minimally invasive and cost-effective (21, 25). 
The endoscopic CO2 laser management of supraglottic tumors, especially for tumors of 
the epiglottis, is an ablative surgical intervention but laser excision can be useful for palliative 
reasons or staging purposes. Experiences from the Department of Otorhinolaryngology in 
Kiel revealed minimal postoperative aspiration but did warn about intraoperative bleeding 
(22, 23). In the latter reports, postoperative irradiation was not recommended because of 
developing edema at the surgical area. 
Bánhídy and Kásler (13) reported that supraglottic tumors were best resected primarily 
by open surgery because of the possible infiltration of the pre-epiglottic space and only in 
exceptional cases could the laser be used for curative purposes. Élo et al. (19) reported 11 
selected epilaryngeal cancer patients successfully treated with endolaryngeal laser excision. 
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Results and development of endoscopic CO2 laser excisions - laser colectomies, 
especially focusing on endoscopic suprglottic laser resections - are presented that were 
performed in the last 12 years at the Department of Otorhinolaryngology, University of 
Szeged. 
1.3. Materials and methods 
At the Clinic of Otorhinolaryngology and Head and Neck Surgery, Faculty of 
Medicine, University of Szeged, Hungary, 170 glottic and 23 marginal supraglottic cancer 
patients underwent curative endoscopic CO2 laser excision during the 12-year period between 
1987 and 1998. 
Among glottic (170 patients) cancers 11 TisNO, 124 TlaNO, 28 TlbNO and 7 T2N0 
tumors were found. Mean age was 60 years. Advanced stage glottic tumors (T2, T3, T4) were 
removed by external approach. 
In the supraglottic (23 patients) group 15 of the patients had T1N0 tumors, 7 patients 
had T2N0 lesions and one patient had a T2N1. Mean age was 52 years. The majority of the 
supraglottic tumors (88%) were operated on by open surgery that involved supraglottic 
laryngectomy with neck dissection. 
Age, social care of the patient and the patient's non-consent to external surgery also 
influences the indications for endolaryngeal laser intervention. 
Glottic (Fig, 1. a, b) and suprahyoid tumors of the epiglottis were treated mostly, but 
tumors of the false cord and aryepiglottic fold (Fig. 2. a, b) were also resected by laser. 
Excision of glottic tumors was carried out as described in the international classification: 
superficial, partial, total and extended cordectomies depending on the extension of tumor. 
Resection of supraglottic tumors was described by Rudert and Werner (22, 23). In 
brief, the epiglottis was cut through in the midline and the incision was carried laterally for 
tumor infiltration. Tumors of the aryepiglottic fold were removed by excision of the 
aryepiglottic fold with partial epiglottectomy. Additionally, endolaryngeal excision of tumors 
was combined with neck dissection when a palpable lymph node was present. 
A Tungsram TLS 61 CO2 laser operating with an output of 10-15 W in a continuous 
mode was applied for laser interventions and was coupled with an Opton microscope. 
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Kleinsasser and Weerda laryngoscopes provided a sufficient exposure of the larynx. All 
procedures were performed under general anesthesia. 
1.4. Results 
1.4.1. Endolaryngeal CO2 laser cordectomy for vocal cord tumors. In the early stage (Tl, 
T2) of vocal cord cancer (170 patients), all tumor was resected by endoscopic CO2 laser. 22 
superficial, 65 partial, 60 total and 23 extended laser cordectomy was performed according to 
the tumor extension respectively. Our results showed a success rate of 85% (144 patients) 
after primary laser cordectomy (100% for T in situ, 87% for Tla, and 67% for Tib and T2 
tumors), which demonstrate the efficacy of this surgical intervention. Quality of voice after 
laser surgery is good and depends on the extension of the laser excision. Salvage treatment 
was required in 26 patients (15%), including 9 repeated laser excision, 5 radiotherapy, 5 
hemilaryngectomy, 2 fronto-lateral, 2 fronto-anterior resection and 3 total laryngectomy and 
thereafter they were free of tumor. Larynx was preserved in 93% of the patients. Mean 
follow-up has been 6.5 years. 
1.4.2. Endolaryngeal CO2 laser excision for supraglottic marginal tumors. Of the 187 
supraglottic cancer patients operated, only 23 (12%) were treated with endoscopic CO2 laser 
resection. This was carried out with neck dissection in one patient. Tumors were located 
mainly on the epiglottis but some had also infiltrated the false cord, too. Sixteen of the 
patients have had no sign of recurrence, for a local control rate of 70%. Radiation therapy (to 
60Gy) was required in one patient as salvage therapy for recurrent tumor after 9 months. 
Laser reexcision was done in three patients. Recurrences were found at 6 months, 9 months 
and 22 months, with no further evidence of tumor subsequently. A horizontal supraglottic 
resection was performed in one patient and total laryngectomy as salvage therapy in another 
patient with no signs of recurrence to date. Repeated laser resections were performed in a 
patient who refused open surgery but this patient became incurable because of tumor 
metastases. The average follow up time has been 38.8 months. 
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Of the supraglottic cancer patients 16 (70%) were free of tumor after a single laser 
resection, 3 after repeated laser resections and 3 after salvage therapy. Larynx was preserved 
in 96% of the patients. 
Some bleedings occurred during laser resection, but complete hemostasis was 
accomplished either with the laser or by electrocauterization for severe bleeding. Some mild 
postoperative perichondritis (4 patients) also occurred in extended excisions. As late 
postoperative complication synechia (3 patients), granuloma (5 patients) turned out. 
No patient had significant postoperative edema, so that no patient required tracheotomy. 
Some patients with supraglottic tumor needed feeding tubes because of postoperative 
aspiration but all tubes were removed in a few days after surgery. 
1.5. Discussion 
In our clinic laser cordectomy is now a routine method for the Tla and Tib glottic 
tumors (14, 16, 21). This method can be safely used for early tumors of vocal cord (13, 14, 
16, 25) but also applicable for tumors of the suprahyoid epiglottis and highly selected cases of 
the infrahyoid epiglottis and other Tl, T2 supraglottic tumors (23, 24). Our results present the 
opportunity of endoscopic laser technique that after getting more familiar with this method, it 
was applied for supraglottic and marginal tumors bringing an extended indication to 
endoscopic laser surgery. Nevertheless, the vast majority of T2, T3, T4 tumors were removed 
by open surgery in our department. 
The limitations of surgery involved our inability to explore the tumor through a 
laryngoscope after being targeted by the CO2 laser and assessment of deep infiltration of the 
tumor. Intra- and postoperative complications involved bleeding that sometimes required 
electrocauterization for control, aspiration managed by feeding tubes and a mild laryngeal 
edema that could be treated by steroid. Postoperative aspiration was not a significant problem 
in any patient. 
The critical area for supraglottic laser resection was the pre-epiglottic space (13, 17, 
23), similar to the anterior comissure for laser cordectomy (14). CT scan is required to detect 
infiltration of the pre-epiglottic space (17). If radiation therapy (60Gy) is used for recurrence 
after laser resection, no severe complications (such as edema) have been seen to date. 
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On the basis of our results, endolaryngeal laser surgery is an applicable method for the 
removal of early glottic tumor and also introduced for selected supraglottic cancers. Neck 
dissection can also be performed together with the endoscopic laser excision if palpable 
metastases are present. 
Endoscopic laser treatment represents a minimally invasive method including less 
traumatizing procedure, shorter hospitalization, shorter operation time, surgery without 
tracheostomy, less operative bleeding and acceptable postoperative quality of voice, by the 
way a better postoperative quality of life. 
Our results shows that endolaryngeal CO2 laser surgery serves an alternative, ablative 
method to open surgery also for patients with selected T1 and T2 supraglottic cancer but one-
third of the patients need salvage therapy. 
Figure 1. a, b. Tla vocal cord tumor before (a) and after laser cordectomy (b) 
Figure 2. a. b. T2 marginal tumor of the larynx (a) and postoperative picture of the healed 
larynx after endoscopic CO2 laser excision (b) 
a b 
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II. Chapter - Immunotherapy: Bispecific antibody 
H.l. Background of immunoptherapy 
Active and passive immunotherapy 
Immunotherapeutical experiments have gained a great importance in the last decade. 
Therapeutic results of surgery, radiotherapy and chemotherapy have not been significantly 
changed but these methods remained the treatment of choice. Immunotherapy can serve as an 
adjuvant treatment for patients, if appropriate application in human will be found. 
Experimentally large spectrum of different types of immunotherapy is under investigation in 
vitro and in animal models and some of them are introduced into the clinical therapy. 
Immunotherapy can be divided into active and passive modalities: 
- Active non-specific immunotherapy: BCG vaccination, hormones and other substances 
that non-specifically activate the immune response 
- Active specific immunotherapy includes gene therapy with non-viral (liposoma) and 
viral vectors mediated gene transmission and vaccination therapy which can activate the 
immune system. 
- Passive non-specific immunotherapy: additional treatment with interleukins (IL-2). 
- Passive specific immunotherapy, monoclonal antibodies coupled with cytotoxic 
compounds or other drugs and bispecific antibodies. Bispecific antibodies (bsAb) has the 
advantage to recognize two different antigens with their Fab region and some of them 
have an intact Fc-region inducing full immune response. 
On the basis of in vitro experiments clinical phase I trials have already been started 
introducing these new techniques to the spectrum of clinical treatments. In our experiments 
bispecific antibody (BiuII) was studied in vitro for the tumor-lytic capacity and its role in the 
complete immune response and clinical consequences are also taken into consideration. So 
that clinical phase I trial has already been started with bispecific antibody at the University of 
Munich. 
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H.2. Role of bispecific antibodies (BiUII) 
Bispecific antibodies (bsAb) are considered to be promising tools for the elimination 
of disseminated tumor cells in a minimal residual disease situation. The bsAb-mediated 
recruitment of an immune effector cell in close vicinity of a tumor cell is thought to induce an 
antitumoral immune response. However, classical bispecific molecules activate only a single 
class of immune effector cells that may not yield optimal immune responses. At the 
University of Munich (Grosshadern, Germany) therefore, an intact bispecific antibody was 
constructed BiUII (anti-CD3 x anti-EpCAM) that not only recognizes tumor cells and T 
lymphocytes with its two binding arms, but also binds and activates Fcy-receptor positive 
accessory cells through its Fc-region. 
Figure 1. Composition of the intact bispecific antibody BiUII. It is a chimeric molecule 
consisting of a rat IgG2b chain that is specific for human CD3 (cluster designation) and a 
mouse IgG2a chain that targets the human pan-carcinoma antigen, Ep-CAM. 
Zeidler et al. (27) demonstrated that activated accessory cells contribute to the bsAb-induced 
antitumoral activity. This detailed analysis of the stimulation demonstrated the BiUII-induced 
upregulation of activation markers like CD83 and CD95 on accessory cells and the induction 
of neopterin and biopterin synthesis. Experiments with pure cell subpopulations revealed 
binding of BiUII to CD64+ accessory cells and CD 16+ NK (natural killer) cells, but not to 
CD32+ B lymphocytes. Further evidence is provided for the importance of the Fc-region in 
that this bispecific molecule stimulates Fcy-R-positive accessory cells to eliminate tumor cells 
in vitro by direct phagocytosis. 
Bispecific antibodies are regarded as efficient tools for the immunological treatment of 
disseminated tumor cells in minimal residual disease situations. Usually, they are constructed 
mouse 
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to target tumor cells by a specific or tumor associated antigen and to recruit one class of 
immune effector cell, either T cells or accessory cells like monocytes or natural killer cells. 
However, long lasting immune reactions in vivo are much more complex and depend on the 
activation of different classes of immune effector cells, especially in the initial phase of the 
immune response. This is usually regarded as the major drawback of conventional bsAb that 
may not yield full immune responses at the tumor site. 
At the University of Munich (Grosshadern, Germany) a new class of bispecific antibody 
was developed that is composed of the two potent subclasses of mouse IgG2a x rat IgG2b. 
BiUII, a member of these new bispecific molecules targets tumor cells via the pan-carcinoma 
antigen Ep-CAM (epithelial cell adhesion molecule) and T-lymphocytes via CD3. In contrast 
to other bispecific molecules (6, 23, 25), it also binds and activates human Fcy-receptor 
positive accessory cells like monocytes/macrophages, NK. cells, and dendritic cells (DCs) via 
its Fc-region. Activation of these accessory cells results in the upregulation of costimulatory 
molecules like CD40, CD80, and CD86, the production of cytokines like EL-2, IL-6 
(inteleukins), and DC-CK1 (dendritic cell derived chemokine) (27). 
Although T cells are considered to be the most important cells for tumor cell elimination, 
they depend on proper antigen presentation by professional antigen presenting cells (APCs) or 
activated accessory cells and costimulatory molecules like CD40, LFA-3 (adhesion 
molecule), CD80 and CD86 in the presence of cytokines such as IL-2 and IL-12 (9, 22). This 
reveals the importance of the subclass combination for induction of activation signals via the 
Fc-receptor of accessory cells. A similar T-cell redirecting bispecific antibody, SHR-1 (anti-
CD3 x anti-CD 19), with the subclass combination of mouse IgGl x rat IgG2b was neither 
able to activate accessory cells via its Fc-region in a clinical study (5) nor in in vitro assays 
without addition of exogenous IL-2 (11). Moreover, the antitumor efficiency of BiUII is 
strongly reduced when T cells alone are used as effector cells. Therefore, we postulated that 
the activation of more than one class of immune effector cell is necessary to provide optimal 
antitumor efficiency. Furthermore, phagocytosis, processing and presentation of the tumor 
material by APCs are prerequisites for the induction of a polyclonal humoral and cellular 
antitumor immune response that we here present. These data are in accordance with the work 
of Clynes et al. (1998) that demonstrated the importance of Fc receptors in passive and active 
immunity in a melanoma model recently (2). 
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H.3. Materials and Methods 
Tumor cell lines and PBMC preparation. PCI-1 (a gift from Dr. T. Whiteside, Pittsburgh, 
PA) is an adherent squamous carcinoma cell line of the head and neck (SCCHN) and is 
maintained in DMEM (cell culture medium) with 10% FCS (fetal calf serum). The cell line 
expresses Ep-CAM but lacks CD80 and CD86 as tested by flow cytometry (data not shown). 
Peripheral blood mononuclear cells (PBMC) were isolated from heparinized blood of 
voluntary donors by Ficoll density centrifugation (3). 
Monoclonal Antibodies. mAbs for FACS analysis were produced by Pharmingen (Hamburg, 
Germany) except the DC-specific antibody, BMA-X11 (Dianova, Hamburg; Germany). 
Generation of dendritic cells (DC). The adherent fraction of PBMCs was incubated for 
seven days in Iscove's medium with 5% FCS (both Gibco BRL, Gaithersburg, MD) and 800 
U/ml of each human DL-4 and GM-CSF (granulocyte/macrophage-colony stimulating factor) 
(both Boehringer Mannheim, Penzberg, Germany). 
Flow cytometry. For FACS® analysis 105 cells were incubated with the primary antibody 
for 30 min on ice in PBS (medium) with 2% FCS. Cells were washed twice in PBS and 
incubated for another 30 min with the second, FITC-labeled antibody. After two final 
washings, propidiumiodide was added and flow cytometry was performed using a 
FACSCalibur® cytometer and the CellQuest analysis program (Becton Dickinson, 
Heidelberg, Germany). For isolation of highly purified CD2+ cells, PBMCs were incubated 
with FITC-labeled specific antibodies and separated on a FACSCalibur®. 
Production of BiUII. The BiUII Quadroma was produced as previously described (Lindhofer 
et al., 1995). The following hybridomas have been used: 26II6 (rat IgG2b, anti-CD3; 
provided by R. Schuh, GSF, Germany) and C215 (mouse IgG2a, anti-EpCAM; provided by 
M. Dohlsten, Pharmacia Upjohn, Sweden) and were also used as parental (monoclonal) 
antibodies. To isolate hybrid Ab molecules of the subclass combination rat IgG2b/mouse 
IgG2a from quadroma, the supernatans were centrifuged, filtered, and loaded onto a 5ml 
Econo Pac protein A column (Biorad, Richmond, CA). After washing with 10 volumes of 
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PBS, antibodies with the hybrid heavy chain configuration were eluted with 0.1M citric acid, 
pH 5.1. 
Cell culture and killing efficiency. For determination of BiUII-mediated killing of tumor 
cells and cytokine production, lxl04 PCI-1 cells/well (targets, =T) were pipetted in 96-well 
flat-bottom plates (Falcon) and PBMCs or subpopulations of PMBCs (=E) were added at E:T 
ratios from 40:1 to 1:1. BiUII was used at 10ng/well in a total volume of lOOpl/ well RPMI 
with 10% FCS. Plates were incubated for 3 days at 37°C in a humified atmosphere (5% CO2). 
Isolation of monocytes/macrophages and NK cells. CD 14+ monocytes/macrophages and 
CD56+/CD3- NK cells were isolated from PBMCs using PE-labeled monoclonal antibodies 
and a Becton Dickinson FACSVantage cell sorter. Purity of isolated cells was examined by 
flow cytometry. 
FITC-labeling of PCI-1 tumor cells. PCI-1 cells were washed twice with Ca2+ and Mg2+ free 
PBS. lpl lmg/ml FITC solution was diluted in 100 pi PBS and was added to 2x10s tumor 
cells and cells were shaken for 30 min at room temperature. Thereafter, FITC-labeled PCI-1 
cells were washed twice with cell culture medium and added to PBMC cultures. The intensity 
of FITC-labeling was monitored by FACS analysis. Phagocytic capacity of PBMC co-
incubated with FITC-labeled PCI-1 cells and BiUII was revealed by FACS after staining with 
PE-labeled mouse-anti-human-CD 14 or -CD 19 antibodies. FITC fluorescence intensity of 
vital CD 14+ or CD 19+ PBMCs was measured and interpreted as uptake of FITC-labeled PCI-
1 tumor cells. Binding of BiUII to PBMC subclasses was revealed by FACS analysis after 
double staining with FITC-labeled mouse-anti-rat antibodies (Dianova, Hamburg, Germany) 
and PE-labeled mouse-anti-human-CD4/CD8, -CD 14, or -CD 19 antibodies. A combination of 
gates (vital cells, CD14+ or CD19+ and FSC vs. SSC) was used to exclude aggregates of PCI-
1 cells with PBMCs from our analysis of phagocytosis of tumor cells. 
MTT-Assay. To assess BiUII-mediated tumor cell killing, a colorimetric MTT-based assay 
was performed as previously described (8). Briefly, PCI-1 target cells were plated in wells of 
a 96-well flat-bottom plate and incubated overnight to get semiconfluent cell monolayers. 
Effector cells were added to the tumor cell monolayers at the appropriate ratios and plates 
were incubated for 24-48 h. After removing of the effectors by washing, 10% MTT solution 
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(0.5 mg/ml; Sigma, Deisenhofen, Germany) was added and plates were incubated for further 
4h. The MTT solution was removed and blue crystals of formazan formed in viable tumor 
cells were dissolved by adding dimethylsulfoxide. The intensity of the color reaction was 
detected at 540 nm in a spectrophotometer and results were calculated based on the mean 
absorbance obtained from at least six wells according to the following formula: % cell death = 
100 x (C-E) / (C-B), where C is the optical density reading of the cells with target cells in the 
absence of effectors (control), B is background without any cell population and E is the 
optical density reading of adherent tumor cells remaining in the wells after co-incubation with 
effector cells. 
Activity of GTP cyclohydrolase I and cellular pterin levels. The activity of GTP 
cyclohydrolase I was determined in the supernatant fraction of the cell extracts (Tris/HCl, pH 
8.0; 2.5 mM EDTA) after acidic iodine oxidation of the reaction product dihydroneopterin 
triphosphate. The neopterin phosphates were separated by ion-pairing HPLC and detected 
fluorometrically. Cellular neopterin and biopterin were determined in aliquots of the cell 
extracts after acidic iodine oxidation, deproteinization by trichloroacetic acid, pre-purification 
by cation-exchange chromatography and separation by reverse-phase HPLC, as described 
previously (10) 
II.4. Results 
II.4.1. BiUII shows excellent tumor lysis in the presence of PBMC 
A new class of bispecific antibody was developed, BiUII that recognizes epithelial tumor 
cells via the pan-carcinoma antigen Ep-CAM (17) and redirects T lymphocytes via CD3. 
BiUII displays an excellent antitumor activity and complete PBMCs are superior to tumor cell 
killing compared to a highly purified T cell population of the same donor with regard to tumor 
cell killing (27). Its tumor-lytic capacity is higher compared to monoclonal antibodies. 
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Figure 2. Lysis of PCI 1 cells. PBMCs from healthy volunteers were incubated with PCI J in 
the presence of BiUII (5ng/100pl), both parental antibodies (5ng/100pl each), or without 
antibodies for two days. Regarding the lytic capacity, BiUII displays much higher lytic 
activity compared to parental antibodies (anti-CD3, anti-Ep-CAM) that were used 
simultaneously. (MTT assay) 
Antibody dependent cellular cytotoxicity (ADCC) is considered to be one of the most 
effective mechanism for destruction of virally infected and tumor cells. Both macrophages 
and dendritic cells express high affinity Fcy-receptor I (CD64) and can be stimulated to 
ADCC by particular subclasses of opsonizing IgG antibodies (Fig. 3 ). 
Figure 3. Killing of PCI 1 cells by monocytes and dendritic cells. Adherent cells derived from 
peripheral blood of a voluntary donor were isolated by plastic adhesion and incubated for 
two days with PCI I with (50 ng/ml) or without bsAb. T cells were not detectable in the 
preparation. Killing of PCI I cells were determined in a MTT assay. 
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Accessory cells are necessary for optimal antitumor activity. Unseparated PMBCs has a 
much higher tumor killing capacity than isolated CD2+ T cells (not shown), so accessory cells 
contributed to the BiuII mediated antitumor activity. 
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II.4.2. BiUII binds to CD3-, FcyR+ accessory cells 
Further evidences are provided that BiUII binds peripheral blood monocytes which express 
the high affinity Fcy-RI, CD64 and how these accessory cells contribute to tumor cell killing. 
To this end, PBMCs were incubated with BiUII and a FITC-labeled anti-rat Ig antibody and 
binding was assessed by F ACS analysis. As depicted in Fig. 4, BiUII binds to CD 14+, albeit 
weakly. Since either antigen recognized by BiUII (CD3 and Ep-CAM) is present on 
monocytes, we concluded that binding of BiUII to Fcy-R-positive accessory cells is most 
probably mediated by the Fc region of BiUII. This finding is in agreement with data published 
(7). In parallel we investigated the binding of BiUII to T and B lymphocytes. T lymphocytes 
express CD3, one target molecule for BiUII, and consequently, a strong binding was 
observed. In contrast, BiUII does not bind to CD19+ B cells that express only the low affinity 
FcyRII, CD32. 
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Figure 4. Binding of BiUII to PBMC subpopidations. PBMCs were incubated with BiUII and 
binding was assessed by FACS analysis. (A) BiUII recognizes, albeit weakly, CD14+ 
monocytes (black line). As monocytes do not express CD3, binding of BiUII is probably 
mediated by the Fc region that binds to FcyRI with high affinity. (B) BiUII strongly binds to 
CD3-expressing CD4+/CD8+ T lymphocytes. No binding of BiUII antibodies was observed 
on CD 19+ B cells. 
II.4.3. BiUII mediated phagocytosis of PCI-1 cells by CD14+ monocytes/macrophages 
Accessory cells contribute to T cell activation and tumor cell elimination in different ways, 
here direct phagocytosis of the tumor cells by CD 14+ cells are shown. To this end, PCI-1 
tumor cells were stained with FITC and co-cultivated with PBMCs for 15 hours in the 
presence of BiUII to assess direct phagocytosis of tumor cells. In control settings, BiUII 
and/or FITC-labeled tumor cells were omitted. After cocultivation, the mean FITC-
fluorescence intensity, indicative for the uptake of labeled PCI-1 cells, was measured in vital 
CD 14+ monocytes or CD 19+ B lymphocytes. As shown in Fig. 5a, uptake of FITC-
fluorescence was triggered in CD 14+ monocytes/macrophages co-cultivated with BiUII. In 
contrast with this, CD 19+ B cells from the same donor showed no signs for PCI-1 uptake, 
even in the presence of the bispecific molecule (Fig. 5b). 
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Figure 5. BiUII stimulates accessory cells to phagocytose PCI tumor cells. FITC labeled PCI 
cells were co-cultivated with PBMCs for 15 hours either with or without BiUII. After 15 
hours, monocytes (CD14+) and B cells (CD19+) were analyzed for the presence of FITC, 
indicating the phagocytosis of PCI cells. (A) The most prominent FITC mean values (248) 
were observed in monocytes incubated in the presence of BiUII. A much lower intensity was 
observed without BiUII (76). Background value of PBMC was 9. Similar results were 
observed after 24 or 48 hours co-cultivation periods (data not shown). (B) In contrast, no 
FITC was incorporated in B cells. 
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II.4.4. BiUII stimulates the production of neopterin and biopterin 
Stimulation of T cells causes release of interferon-y, which in turn, induces increased 
expression of GTP cyclohydrolase I in monocytes/macrophages and in T cells (20, 29). This 
enzyme initiates and controls the biopterin synthesis pathway. Therefore, activated T cells 
produce tetrahydrobiopterin, whereas monocytes/macrophages cannot complete the pathway. 
They terminate the synthesis pathway after the first step and instead of accumulating and shed 
neopterin. Increase in the activity of GTP cyclohydrolase I and the synthesis of neopterin and 
biopterin are therefore indicators of monocyte/macrophage and of T cell activation, 
respectively (29). Fig. 6 demonstrates that BiUII induces GTP cyclohydrolase activity and 
enhances the production of neopterin and biopterin in PBMC after cocultivation with tumor 
cells in the presence of BiUII. These facts indicate the activation of T cells and monocytes. 
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Figure 6. BiUII induces GTP-cyclohydrolase I activity and the production of neopterin and 
biopterin in monocytes/macrophages. PCI-1 cells were co-cultivated with PBMCs either with 
(100ng/ml) or without BiUII for two days. (A) The production of neopterin and biopterin and 
(B) the activity of GTP cyclohydrolase was determined. BiUII stimulates the production of 
both biopterin and the monocyte-specific neopterin, as well as the activity of the enzyme. PCI-
1 cells per se are negative for all three products. 
21 
II.4.5. BiUII activates natural killer (NK) cells for tumor cell lysis 
NK cells are known to play a pivotal role in the elimination of tumor cells. Since NK cells 
express the low affinity FcyRJII (CD 16), it is supposed that BiUII not only binds to CD64+ 
monocytes/macrophages but also to CD16+ NK cells. Therefore highly purified CD56+/CD3-
NK cells were isolated, incubated with BiUII and the binding of the bispecific antibody was 
analyzed by FACS analysis. Binding of BiUII to NK cells via CD16 should lead to their 
activation, resulting in an antitumor activity. BiUII-mediated induction of CD95 on NK cells 
was studied: the main question was whether this activation marker is recognized for these 
cells (16, 19) and tumor cell killing was investigated by BiUII-activated NK cells. Addition of 
BiUII to the cell culture induces the expression of CD95 on CD3-/CD16+NK cells indicating 
their activation via the Fc region of BiUII. Consequently, co-cultivation of NK cells with 
allogeneic PCI-1 tumor cells in the presence of BiUII resulted in enhanced tumor cell killing 
(Fig. 7). NK cells per se display a remarkable activity against allogeneic cells. However, this 
cytotoxicity was further enhanced by the addition of BiUII. 
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Figure 7. NK cells are stimulated to kill allogeneic tumor cells after incubation with BiUII. 
Highly purified CD56+CD3- NK cells (effectors - E) were cocultivated with PCI-1 cells 
(target - T) at different E/T ratios for two days either with (lOOng/ml) or without BiUII. 
Killing of tumor cells (targets) was calculated in a MTT assay as described in Material and 
Methods. 
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II.4.6. BiUII induces the upregulation of costimulatory molecules on dendritic cells (DC) 
The network of dendritic cells (DCs) is another class of key regulators of immune 
responses. DCs are potent antigen presenting cells (21) and trigger the activation of T cells 
e.g. via the CD40-dependent pathway (15). Activation of DCs is characterized by the 
neoexpression of CD83 (3, 28) and upregulation of costimulatory molecules (1). Thus, DCs 
are thought to be involved in the generation of cytotoxic T cells (1, 18). 
The objective of this study was to investigate whether DCs are activated by BiUII. 
DCs were generated from the adherent fraction of PBMCs by incubating these cells for two 
weeks in the presence of IL-4 and GM-CSF. The percentage of DCs in the culture was 
checked by staining with the DC-specific antibody BMA-X11 and was shown to be >80% 
(not shown). Then, DCs were incubated overnight either with BiUII (lOOng/ml) or left 
untreated in cell culture medium. After 16 hours, the expression of surface markers CD83 and 
CD86 was revealed by FACS analysis. As shown in Fig. 8, incubation of DCs in the presence 
of BiUII leads to the upregulation of both CD83 and the co-stimulatory signal CD86, 
indicating the activation of DCs mediated by BiUII. 
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Figure 8. Induction of CD83 and CD86 on dendritic cells. Addition of BiUII for one day to a 
culture of DCs leads to the upregulation of the activation marker CD83 (A) and the 
costimulatory molecule CD86 (B). Only cells positive for the DC marker BMA-X11 were 
considered for this analysis. With BiUII: black line; without BiUII: gray trace. 
IL5. Discussion 
This study demonstrates that not only the two specific binding arms but also the Fc-region 
of a bispecific antibody can contribute to the activation of immune effector cells and thus to 
anti-tumor activity. However, binding of Fcy-receptors and activation of Fcy-R expressing 
cells strictly depends on the composition of the Fc region of the bispecific molecule. Mouse 
IgG2a and rat IgG2b are two evolutionary related, potent effector subclasses that, in 
combination, exert efficient activation of human accessory cells. This is shown by the 
upregulation of costimulatory molecules and activation markers like CD83, CD86, and CD95, 
the upregulation of neopterin synthesis, the direct phagocytosis of tumor cells by purified 
monocytes, and the direct killing by isolated accessory cells without the contribution of T 
cells. Interestingly, PBMCs were only weakly activated by equimolar amounts of the two 
parental monoclonal antibodies (27). 
Conventional bsAbs are usually composed of one potent subclass like mouse IgG2a or rat 
IgG2b and a less potent subclass like mouse IgGl (5), or even two less potent subclasses (26). 
As a consequence, the Fc-region of conventional bsAbs usually is not able to activate human 
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accessory cells. Instead, these bispecific molecules bind and activate a single class of effector 
cell via one of their binding arms. This system has the drawback that in the case of T cells, an 
isolated activation via the CD3 molecule without appropriate costimulatory signals may cause 
activation-induced anergy (4). This is why our working group decided to work out a 
bispecific antibody that activates more than one class of immune cell, a situation that much 
more resembles inflammatory and immune reactions in vivo. The potential of such new bsAbs 
in tumor eradication has been already shown in animal models (12). The aim of the 
experiments presented was to reveal the mechanisms that are induced by this new agent. 
Therefore, our experiments demonstrate the activation of accessory cells that either express 
Fcy-RI (monocytes/macrophages and DCs) or Fcy-RIH (NK cells). We also presented that e.g. 
monocytes/macrophages not only are activated but also directly contribute to the anti-tumor 
activity of BiUH by phagocytosis. In contrast, this mouse IgG2a x rat IgG2b bispecific 
molecule does not bind to B lymphocytes that express the low affinity receptor, CD32. 
Enhanced production of tetrahydrobiopterin after BiUII stimulation may also participate in 
the modulation of cell functions, e.g. by increasing NO production (14). Furthermore, 
accessory cells deliver molecules CD40, CD80 and CD86, important for T cell activation (15, 
24), and produce pro-inflammatory cytokines (27). The significance of accessory cell 
activation is underlined by data recently published that demonstrate the importance of CD28 
costimulation for the prevention of activation-induced T cell death in a bsAb-immunotherapy 
trial (4). 
The most important aspect of the system is that due to the recruitment of different 
immune effector cells, BiUII-mediated immune complexes represent a self-supporting system 
that is not dependent on the addition of exogenous IL-2 (interleukin), a fact that is extremely 
advantageous for in vivo applications. The concerted activation of T cells and accessory cells 
at the tumor site, leading to the phagocytosis, processing and presentation of tumor material 
may account for the potential of this new class of intact bispecific antibody and is a 
prerequisite for a polyclonal humoral and cellular immune response. Although HAMA 
(human anti-mouse antibody) or HARA (human anti-rat antobody) reactions in vivo cannot be 
excluded, especially after repeated applications, this new class of bispecific molecule may 
represent a promising tool for the adjuvant treatment of cancer patients. 
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III. Chapter - Tumor immunology/ therapy: 
Beneficial effects of the non-steroid anti-inflammatory drugs (NSAIDs) on 
the antitumoral immune response 
IH.l Background of immunosuppression 
Immunosuppressive effects of tumors are supposed to have a major role in the insufficient 
development of cellular and humoral immune response. Adhesion and chemotaxis of 
accessory cells can be influenced by tumors producing factors that inhibit these complex 
immune processes. Blocking the adhesion and chemotaxis of accessory cells like monocytes 
from the blood vessels results in a partial and slower activation of immune cells and target-
tumor cells that should be eliminated by the immune system would be hardly affected leading 
to persisting tumor cells. Prostaglandin E2 produced by tumor cell lines acts as an 
immunosuppressive factor. These immunological effects have been studied with special 
regard on adhesion chemotaxis of monocyte function. Tumor cells derived from different 
tumors regularly produce PGE2 interfering with the function of monocytes. In particular, 
PGE2 inhibits the potential of monocytes to migrate in the direction of a chemotactic stimulus 
and to adhere to endothelial cell. This inhibition is most probably due to a modulation of the 
chemokine receptor CCR5 and the Ji2-integrin Mac-1. Both downregulation of CCR5 and 
reduced expression of Mac-1 may diminish the potential of peripheral blood monocytes to 
leave blood vessels and invade target tissues. 
The cyclooxygenases (COX)-l and COX-2 are key enzymes in the conversion of 
arachidonic acid to prostaglandins and other eicosanoids. While COX-1 is expressed 
ubiquitously, COX-2 is an immediate-early gene, its expression is often associated with 
malignant transformation and a role for the COX enzymes in tumor initiation and promotion 
is discussed (17). Non-steroidal anti-inflammatory drugs (NSAIDs) like aspirin and 
indomethacin that block COX-1 and -2 have been shown to have beneficial effects for tumor 
patients (3, 4, 5). Therefore, these compounds have gained interest among oncologists. 
However, the molecular mechanism by which NSAIDs inhibit carcinogenesis is not clearly 
understood. Both prostaglandin-dependent and -independent effects may account for their 
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antineoplastic action. Since both dysfunctions can be restored with NSAIDs, our findings 
contribute to the understanding of the molecular chemopreventive action of NSAIDs on tumor 
formation and progression. 
m.2. Role of PGE2 and its immunological effects on the functions of immune cells 
Cyclooxygenases (COX)-l and COX-2 are key enzymes of the biosynthetic pathway of 
prostanoid formation. Both COX-1 and COX-2 are blocked by non-steroidal anti-in-
flammatory drugs (NSAIDs) (1). Whereas COX-1 is constitutively expressed in many types 
of tissue (2), COX-2 is an immediate-early gene that is induced in inflammatory cells by 
mitogens, tumor promoters and cytokines. Cyclooxygenases became of special interest to 
oncologists since overexpression of COX-2 was demonstrated in human tumors (3) and 
epidemiological studies revealed that continuous use of NSAIDs reduces the risk of 
development of different cancers (4, 5). In addition, a causative role for the COX enzymes in 
tumor development and progression as well as metastatic behavior has also been 
demonstrated (6-8). Since elevated prostaglandin E2 (PGE2) levels occur in various cancers 
(9, 10), inhibition of the COX isoenzymes is probably an important function of NSAIDs (11-
13). However, PGE2-independent effects have also been described (4, 14-16) and the 
molecular mechanisms of the chemopreventive antineoplastic action of NSAIDs remained 
largely unclear. For a summary of COX-dependent and independent NSAIDs actions were 
recently discussed in details (17). 
Leukocytes that circulate in the body have to exit the blood stream in order to exert their 
immunological function. Leukocytes adhere to endothelial cells at the luminal side of blood 
vessels, transmigrate and enter target tissues (18). The adhesion is a complex process that 
involves a plethora of different molecules like the 152-integrins (CD 11 a/CD 18; CD1 lb/CD 18, 
and CDllc/CD18) (19). The pivotal immunological significance of 152-integrins is obvious 
from leukocyte adhesion deficiency type I (LAD-I), a clinical condition that is caused by a 
mutation in the 152-common CD 18 chain. Patients suffering from LAD-I usually die at young 
age due to multiple leukocyte defects (20). 
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Chemokines are small proteins that function as emergency signals produced locally in 
response to inflammation and immune responses (21). Chemokines induce chemotaxis of 
leukocyte subsets and stimulate their adhesion to the endothelium (22). Chemokines signal 
through specific seven-transmembrane domain, G-protein coupled receptors (23). CCR5, one 
of these receptors, is expressed on monocytes, certain lymphocytes and binds macrophage 
inflammatory protein alpha (MlPla), macrophage inflammatory protein beta (MIP1|3), and 
RANTES (regulation on activation, normal T cell expressed and secreted) (24). CCR5 has 
gained special interest when it was identified as the fusion-cofactor for macrophage-tropic 
HIV (25). The physiological role of CCR5 in activation and migration of monocytes, 
however, has been studied to a much lesser extent. 
Just recently, it has been demonstrated that PGE2 downregulates CCR5 surface 
expression on monocytes rendering these cells resistant to HIV (26). Since the COX 
isoenzymes are often overexpressed in human tumors and PGE2 is the major metabolite of 
arachidonic acid metabolism, we asked whether tumor derived PGE2 interferes with the 
physiological activity and function of monocytes. 
We show here that PGE2 derived from human carcinoma cell lines causes 
downregulation of the surface expression of CCR5 and the adhesion molecule Mac-1 on 
monocytes. Downregulation results in a reduced competence of monocytes to respond to a 
chemoattractant (MIP-1P) and to adhere to endothelial cells. In addition, conditioned tumor 
supernatants induce high level production of IL-10 (interleukin-10) and TNFa (tumor 
necrosis factor alpha) in monocytes. These effects can be inhibited by NSAIDs as aspirin and 
indomethacin. Since adhesion and migration are also pivotal steps in the recruitment of 
effector cells into the tumor stroma and the subsequent eradication of tumor cells (27), their 
inhibition may have implications on tumor development. Our findings provide a new 
molecular explanation for the beneficial effects of aspirin and indomethacin on tumor 
incidence and may have clinical consequences for the treatment of cancer patients. 
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m.3. Materials and Methods 
Tumor cell lines, cytokines, and PGE2 
FaDu (HTB-43, ATCC, Manassas, VA) and PCI-1 (a gift from Dr. T. Whiteside, 
Pittsburgh) are cell lines derived from squamous cell carcinoma of the head and neck and 
GHD-1 is a permanent cell line derived from a hypopharynx carcinoma that was established 
in our laboratory. MCF-7 (HTB-22; ATCC) is a human mammary carcinoma and HCT-8 
(CCL-244; ATCC) is a human colon carcinoma cell line. All cell lines used were maintained 
as continuously growing monolayers in DMEM with 10% FCS (both from Seromed, Berlin, 
Germany). Recombinant human TNFa and IL-10 were from Boehringer Mannheim 
(Mannheim, Germany), PGE2 was from Sigma (Munich, Germany). 
Generation of cell-free tumor cell supernatants (FaDu-SN) 
Tumor cells were seeded at 10"* cells/ml and grown for two days in DMEM at 37°C. 
Supernatants were harvested, centrifuged and passed through a 0.2pm Acrodisc low protein 
binding filter (Gelman Sciences, Ann Arbor, MI). IL-10, TNFa and PGE2 production was 
determined with commercial ELISA assay (R&D Systems; Wiesbaden, Germany) according 
to the manufacturers instructions. PGE2 production given in Table 1 represents the mean of 
three different experiments (SD <20%). 
Flow cytometry 
For FACS® analysis 105 cells were incubated with the primary antibody for 30 min on ice 
in PBS containing 5% FCS. The cells were washed twice in PBS and incubated for another 30 
min with the second FITC-labeled antibody. After two final washings, propidiumiodide was 
added and flow cytometry was performed using a FACSCalibur® cytometer and the 
CellQuest analysis program (Becton Dickinson, Heidelberg, Germany). 
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Adhesion assay 
For monocyte adhesion, peripheral blood monocytes were incubated for two days either 
in DMEM or in undiluted conditioned tumor cell supernatants. Primary endothelial cells from 
umbilical blood cords (10.000 cells/per well) were seeded in 96-well plates at half-confluency 
and kept for two days in Endothelial Cell Growth Medium (Promocell, Heidelberg, 
Germany). After two days the endothelial cells had reached confluency. Monocytes were 
labeled for 30 min at 37°C with 20 pM fluorochromic dye, CMFDA (Molecular Probes, 
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Eugene, OR) and washed twice with PBS. 2x10 monocytes were than added to the 
endothelial cell layer for 30 min to promote adherence. Plates were washed three times and 
supernatant was removed almost completely. The 96-well plate was then covered, inversed 
and centrifuged for 10 min at 500xg at room temperature. The number of adhering monocytes 
was determined by measuring fluorescence at 525 nm in a Wallac 1420 Victor multilabel 
counter (Wallac, Turku; Finland). For adhesion to recombinant human ICAM-1 (intercellular 
adhesion molecule), 293 cells were transfected with an expression plasmid encoding a fusion 
protein of the Fc part of a human immunoglobulin (IgGl) and ICAM-1 (Fc/ICAM-1; a gift 
from Dr. W. Kolanus, Munich) and the supernatants were collected four days after 
transfection. Culture dishes (Falcon 1008) were first coated for 1.5 hour with a human IgG-
specific antibody (5pg/ml; Dianova, Hamburg; Germany) in 50mM Tris-Cl, pH 9.4 and then 
for 4 hours at room temperature with the supernatant from transfected 293 cells. Dishes were 
washed twice to remove unbound ICAM-1 and monocytes were added for two hours. After 
two final washings, adherent cells were trypsinized and counted. 
Monocyte migration 
For cell migration assays 2x10^ monocytes were pre-cultivated for one day in either 
DMEM or undiluted conditioned FaDu-SN. Monocytes were then placed on 8-pm pore size 
polycarbonate filters (Nunc, Roskilde, Denmark) and allowed to transmigrate for 4 hours in 
the direction of MIPip (20ng/ml; R&D Systems, Heidelberg, Germany) in the lower 
chamber. Migrated cells were pelleted, stained with Giemsa black and counted under light 
microscopy. Mean values of migrated cells were calculated from 3 wells/supernatant. 
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m.4. Results 
m.4.1. Tumor cell supernatants induce the production of IL-10 and TNFa 
Tumor samples derived from head and neck cancer and from other locations as well as 
permanent tumor cell lines have been shown to produce PGE2 (28-30). Most of the tumor cell 
lines we used for our investigations also produce PGE2 (Table 1). Since PGE2 induces IL-10 
production (30), we first asked whether these tumor cell lines also synthesize this immuno-
suppressive cytokine. ELISA assays performed with conditioned tumor cell supernatants (Tu-
SN), however, revealed that none of these cancer cell lines produce detectable amounts of IL-
10 (Fig. 1). The fact that IL-10 synthesis has been described in freshly excised tumors (31-
33), prompted us to investigate whether these tumor cells induce IL-10 production in primary 
peripheral blood monocytes. Therefore, cultivated monocytes were kept in conditioned tumor 
supernatants or in DMEM cell culture medium for two days. Monocytes per se produce only 
small amounts of IL-10 but synthesis of this cytokine is dramatically induced by cultivation of 
monocytes in tumor supernatants for two days (Fig. 1). 
TNFa is a cytokine that has been described being induced in monocytes stimulated with 
human cancer cells (34). TNFa mostly displays proinflammatory properties but is also able to 
block T cell proliferation (28, 35). We again performed ELISA assays which demonstrated 
that conditioned Tu-SN not only induces IL-10 but at the same time the production of TNFa 
in monocytes (Fig. 1). 
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Figure 1. Supernatants of tumor cell lines derived from head and neck, breast, and colon 
cancer induce IL-10 and TNFa production of primary monocytes. All tumor cell lines tested 
neither produced IL-10 nor TNFa per se and only small amounts of these compounds were 
detectable in primary monocytes. However, identical conditioned tumor-SN induced the 
production of both cytokines in monocytes after cultivation in 100% conditioned media for 
two days. Mean values of three experiments are shown, samples were utilized in duplicates. 
The GHD-1 cancer cell line that does not produce PGE2 (Table 1) does not induce cytokine 
production (not shown). 
Cell line PGE2 
(pg/ml) 
CCR5 Mac-1 
FaDu 200 1 I 
PCI-1 >4.000 I t 
GHD-1 0 - -
HCT-8 185 1 i 
MCF-7 165 I I 
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Table 1. PGE2 production in various tumor cell supernatants and their effects on CCR5 and 
Mac-J expression on monocytes as observed by FACS analysis. All tumor cells tested produce 
PGE2, albeit at varying concentrations. The mean values of three independent experiments 
are given. Samples were utilized as duplicates, SD was below 20%. The influence of these 
conditioned supernatants on CCR5 and Mac-1 expression on primary monocytes is 
heterogeneous and argues for the presence of additional immunomodulating factors others 
than PGE2. For determination of CCR5 and Mac-1 expression, primary monocytes derived 
from healthy volunteers were cultivated for two days in these conditioned media prior to 
FACS analysis. The reason of upregulation of Mac-1 after incubation of monocytes in PCI-1 
supernatants needs further investigations. 
m.4.2. Tumor cell supernatants (TU-SN) downregulate surface expression of CCR5 
CCR5 is a chemokine receptor, which is expressed on monocytes and certain T 
lymphocytes (24, 36). It has been identified as a co-receptor for HIV-entry (25) but its 
physiological role is activation and regulation of responses to chemokines. In order to 
investigate the influence of tumor cell supernatants on the surface expression of CCR5, we 
cultivated freshly isolated monocytes for two days in different types of conditioned tumor cell 
media and investigated CCR5 by FACS analysis. Vitality of monocytes was usually >90% 
and was not influenced by Tu-SN as tested by trypan blue exclusion. As demonstrated in Fig. 
2a, the incubation with Tu-SN led to a significant downregulation of CCR5 in comparison to 
incubation with cell culture medium. Supernatants from a tumor cell lines that does not 
produce PGE2 (GHD-1) did not show this effect (data not shown). Most likely, this effect is 
mediated by PGE2 present in the tumor cell supernatants since the observed effect can be 
inhibited by aspirin (Fig. 2b) and indomethacin (not shown) and stimulated with purified 
PGE2 (Fig. 2c). 
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Figure 2. Tumor-SN downregidate the expression of CCR5 on monocytes. (A) Incubation of 
monocytes for two days with FaDu-SN resulted in a clear downregulation of CCR5 (black 
line) in contrast to cell culture medium (gray trace). This effect coidd be abolished, when 
FaDu cells had been grown in the presence of ImM aspirin (B) or 13 pM indomethacin (C). 
CCR5 was similarly downregulate, when purified 1x10 5 M PGE2 was added to the cell 
culture medium (D). 
III.4.3. Tu-SN reduce the chemotaxis of monocytes 
Chemokines are produced locally in response to infections and immune reactions. The 
migration of immune cells in the direction of higher chemokine concentrations is necessary 
for efficient immune responses (21, 37, 38). Since MIP-ip, which is produced by activated T 
cells (21) binds to CCR5, and Tu-SN downregulate CCR5, we performed a chemotaxis assay 
in order to determine whether CCR5-downregulation results in a reduced ability of primary 
monocytes to migrate in direction of higher MIP-ip concentrations. Therefore, primary 
monocytes were cultivated for one day either in FaDu-SN or in cell culture medium. 
Migration was then performed against MIP-ip (20 ng/ml) for 3 hours through 8-pm pore 
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filters. As pointed out in Fig. 3, the pretreatment of monocytes with FaDu-SN significantly 
(p<0.003) reduces the number of migrated monocytes to approximately 50% compared with 
DMEM. Migration inhibition was partially abrogated by cultivation of FaDu cells in the 
presence of ImM aspirin. 
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Figure 3. FaDu-derived factors interfere with the migration of monocytes. Isolated 
monocytes were cultivated for one day either in conditioned FaDu-SN or in cell culture 
medium (DMEM).. Migration was reduced to almost 50% after incubation in FaDu-SN and 
was much less inhibited, when FaDu-SN were generated in the presence of ImM aspirin 
(FaDu-SN + Asp). Results represent the mean of 4 values, p<0.003 (paired Student's test). A 
representative residt of three independent experiments is shown. 
III.4.4. Tu-SN downregulate adhesion molecules on monocytes and inhibit adhesion 
As demonstrated in a recent study, the number of immune cells in the tumor infiltrate is 
increased after administration of indomethacin (39). Since adhesion to the endothelium is 
another pivotal step for leukocytes in order to leave the blood stream, we investigated whether 
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Tu-SN also inhibit the function of the P2-integrin Mac-1 on monocytes. We incubated 
monocytes for two days either in cell culture medium or conditioned tumor supernatants and 
investigated surface expression of Mac-1 by FACS. We found that both chains of Mac-1, 
CDllb and CD18, were clearly downregulated after incubation in FaDu-SN (Figure 4). This 
modulation was not observed when FaDu-SNs were generated in the presence of aspirin or 
indomethacin (not shown). 
Figure 4. Downregulation of Mac-1 expression after incubation of monocytes in FaDu-SN: 
Monocytes were incubated for two days either with FaDu-SN (black line) or with cell culture 
medium (gray trace) and investigated for Mac-1 expression. Both chains of the molecule, 
CDllb and CD 18 were clearly downregulated after incubation in FaDu-SN in comparison to 
cell culture medium. Similar results were observed after addition of purified PGE2 to the 
medium. FaDu-SNs, that were generated in the presence of aspirin (1 mM) and indomethacin 
(13 pM) did not show this effect (data not shown). 
The main ligand for Mac-1, ICAM-1 is expressed on endothelial cells and this interaction 
is pivotal for adhesion and extravasation of monocytes (40). Therefore, we next investigated 
whether downregulation of Mac-1 has consequences for the adhesion of monocytes to 
recombinant ICAM-1. To this end, cell culture dishes were coated with a fusion protein 
Fc/ICAM-1 and monocytes that were preincubated with FaDu-SN, FaDu-SN that has been 
generated in the presence of 1 mM aspirin, purified PGE2, or cell culture medium only. It has 
been demonstrated that FaDu-SN and purified PGE2 strongly inhibited the binding of 
monocytes to ICAM-1, whereas FaDu-SN that was generated in the presence of aspirin had a 
much less dramatic effect on this process (Figure 5A). 
36 
In an additional set of experiments we investigated whether tumor supernatants also 
interfere with the adhesion of monocytes to endothelial cells. We isolated human umbilical 
cord endothelial cells and monocytes and pretreated them with DMEM or FaDu-SN. 
Monocytes were then labeled with CMFDA (5-chloromethylfluorescein diacetat) and put onto 
the endothelial cell layer for 30 min. After intensive washings, adherent monocytes were 
counted with a fluorometer. As shown for recombinant ICAM-1, FaDu-SN also reduced the 
adhesion of monocytes to endothelial cells (Fig.5B). 
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Figure 5. (A) Incubation of monocytes with FaDu-SN reduces adhesion to endothelial cells 
and ICAM-1. 
(B) For binding of monocytes to endothelial cells, pretreated monocytes were added to a 
confluent monolayer of endothelial cells for 30 min. Adhesion of monocytes in DMEM was set 
to 100%. 
III.5. Discussion 
Tumor immunity, i.e. the evasion of tumor cells from recognition and subsequent 
elimination through the immune system is one of the most intensively investigated aspects of 
tumor etiology. In order to evade immune cell attacks, tumors have established escape 
mechanisms: they downregulate MHC class I and II molecules to become "invisible" to T 
lymphocytes, do not express costimulatory molecules necessary for proper T cell activation, 
and/or produce immunosuppressive factors that interfere with the activity of immune cells. 
38 
The development of malignant tumor cells is a multi-step process mostly explained by 
genetic mutations and altered protein expression. Deregulation of lipid metabolism has been 
considered less often as a tumorigenic factor. Although the immunosuppressive effects of 
PGE2 are now known for several years (41), cyclooxygenases and metabolites of arachidonic 
acid only recently gained interest by oncologists, too. This may be attributed to clinical 
observations in cancer patients where the long-time application of aspirin and indomethacin 
has positive effects on the tumor rate (4, 42, 43). Along this line, animal models clearly 
demonstrated that chemokines and blockade of PGE2-synthesis improved the quality and 
quantity of the tumor infiltrate resulting in reduced tumor growth in vivo (44-48). 
Most effects of PGs are probably exerted through an elevation of intracellular cAMP 
levels. However, the exact mechanism how PGs perform their immunosuppressive effects are 
not fully understood. Here we demonstrate that tumor-cell derived PGE2 causes 
downregulation of the chemokine receptor, CCR5, and the 152-integrin, Mac-1 on monocytes. 
A summary of our results is presented in Table 2. 
monocytes cultivated in DMEM mean values effect 
with: CDllb 
TNFa (lOOU/ml) 
PGE2 (10-5M) 
IL-10 (50ng/ml) 
TNFa + IL-10 
TNFa + PGE2 
Table 2. Effects of TNFa, IL-10 and PGE2 on CDllb levels on primary monocytes. 
Monocytes were incubated for two hours with the cytokines indicated and investigated by 
FACS. TNFa induces CDllb expression, whereas IL-10 and PGE2 provoke a 
downregulation. IL-10 and PGE2 also efficiently block TNFa induced upregulation. 
As a consequence, the ability of these monocytes to adhere to the endothelial cells and to 
migrate in the direction of higher concentrations of the chemoattractant MIPip is strongly 
reduced. Since both processes are pivotal for efficient tumor cell elimination, this may 
describe a new strategy of tumoral escape from immune responses. Impaired leukocyte 
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migration due to PGE2-mediated downregulation of CCR5 may also explain why 
administration ofNSAIDs increases the number of immune cells in the tumor bed in patients 
with head and neck cancer (39). Downregulation of CCR5 and Mac-1 was not due to toxic 
factors in tumor cell supernatants since viability and MHC class I and CD86 expression levels 
were not and CD80 was only marginally affected (not shown). In addition, tumor cells induce 
the production of the immunomodulating cytokines IL-10 and TNFa in monocytes, which 
may also contribute to the inactivation of monocytes and probably other leukocyte subsets. 
In summary, we describe here the downregulation and partial loss of function of two 
PGE2 target molecules on monocytes (CCR5, Mac-1). These phenomena result in a reduced 
potential of monocytes to adhere to endothelial cells and migrate in the direction of the 
chemoattractant MIP-ip. The significance of our observations is further supported by a report 
demonstrating enhanced tumor growth and reduced monocyte recruitment in animal models 
after blocking Mac-1 or the chemokine MCP-1 (49). In addition, tumor derived PGE2 also 
induces the production of EL-10 which is known to inhibit immune cell function (50-52). 
Tumor derived PGE2 also induces TNFa that has been described to inhibit T cell proliferation 
(28, 35) and downregulation of CCR2 on monocytes (53). Since the number and composition 
of tumor infiltrating leukocytes is probably one of the key parameters for the clinical 
prognosis of cancer patients (44, 47, 54), our data may provide the first molecular explanation 
for the beneficial therapeutic effects of non-steroid anti-inflammatory drugs like aspirin and 
indomethacin in tumor patients. 
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Conclusions 
Treatment of head and neck cancer, especially laryngeal and hypopharyngeal tumor is 
a great challenge for the head and neck surgeon. The relative poor prognosis of these tumors 
is associated with the high metastatic rate except glottic tumor. Traditionally curative 
techniques like surgery, chemo- and radiation therapies are applied but the result - survival 
and quality of life - is highly depends on early detection of the tumor and proper therapy: 
surgical technique including minimally invasive endoscopic excision, radiation therapy, 
chemotherapy and - in the future - immunotherapy or gene therapy. 
1. Endoscopic COlaser study: 
At the Department of Otorhinolaryngology, Head and Neck Surgery, University of 
Szeged surgery is the primary treatment for most laryngeal tumor representing a large 
spectrum of endoscopic and external surgery (partial or total laryngectomy, pharyngectomy). 
As a result of the described study we started to use a new method: In almost all early 
stage glottic cancer (Tl, T2) endoscopic CO2 laser became a routine method introduced in 
1987 at our department (I.). Later having experience with this treatment we extended this 
technique - as a new method in the removal of this type of tumor - for selected supraglottic 
tumors (Tl, T2). In those cases endoscopic CO2 laser surgery became also an applicable, 
minimally invasive method with good postoperative quality of life. Endoscopic laser 
treatment now provides a preferable method - less stress, complication, hospitalization - for 
the patient with Tl, T2 glottic and selected cases of supraglottic tumors versus external 
approach (IV., V., VI., VII.,X., XI.) but certainly it has limitations. Endoscopic C02 laser 
excision provides a better postoperative quality of life (QOL), so it can play an important role 
in the indication. In our clinic, endolaryngeal CO2 laser is basicly used for glottic cancer and 
tumor of the epiglottis but in selected cases of T2 supraglottic and marginal tumors it is 
utilized, too. Advanced stage tumors (T3, T4) can be removed only by external surgery (VII.). 
41 
2. Immunotherapy: 
By now result of recent treatment modalities shows no improvement in the survival 
rate so beside the refinement of surgical, radiological and chemotherapeutical techniques 
research has shifted to the experimental and clinical trial of immunotherapeutical and gene 
therapautical methods. These methods act at cellular and genetic level to eliminate tumor cells 
and/or restore the normal immune response. 
New immunotherapeutical method was introduced: Bispecific antibody belongs to the 
passive specific immunotherapy. Bispecific antibody (BiUII) produced and used at the 
University of Munich is a promising in vitro tool for the treatment of minimal residual disease 
(tumor), fighting against residual tumor cells and the development of metastasis. BiUII (anti 
CD3/anti Ep-CAM) with an intact Fc-region is able to redirect T cells and accessory cells to 
tumor cells restoring the normal immune response. 
The working group at Department of Otorhinolarynglology, University of Munich 
achieved complex immune response in our in vitro experiments, tumor cells were killed by 
BiUII-activated immune cells. Our results presented the investigation of the lytic capacity of 
BiUII by monocytes/macrophages and dendritic cells, and functions of accessory cells in the 
immune response with bispecific antibody. Our experiments revealed that intact Fc region of 
the bispecific antibody contributes to the full immune response showing activation of CD 14+ 
monocytes, dendrtitic cells, CD56+ NK cells and costimulatory molecules (CD83, CD86). 
Furthermore, lytic capacity of the bispecific antibody proved to be excellent by full activation 
of all class of immune cells. Binding of accessory cells by bispecific antibody and increased 
phagocytic activity of accessory cells were also presented (IX., XII.). 
In vivo clinical phase I trial has already started to test the efficacy of these new 
bispecific antibody in human. A cooperative study is planned with the participation of the 
University of Munich and University of Szeged, Department of Otorhinolaryngology, Head 
and Neck Surgery to carry out immunotherapeutical experiments and clinical trials. 
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3. Tumor immunology/ therapy: 
Immunosuppressive conditions can lead to malignant transformation of the cell due to 
genetic alteration and dysfunction of immune cells. Prostaglandin E2 known as 
immunosuppressive molecule which is present in the surrounding of tumor cells. In our 
experiments at the University of Munich dysfunction of macrophages/monocytes was shown 
in immunosuppressive condition. Chemotaxis and migration of these immune cells were 
reduced by tumor cell supernatants and expression of CCR5 receptor and P2 integrin Mac-1 
were significantly diminished that affects the ability of monocytes to leave the blood vessels 
and to migrate to target (tumor) cells to invade and eliminate them. Effect of PGE2 could be 
restored at least partially by additional treatment with non-steroid anti-inflammatory drugs 
(NSAIDs) like aspirin or indomethacin. Treatment with NSAIDs displays a beneficial effect 
on the function of monocytes, which was inhibited by PGE2 and can serve as a molecular 
chemoprevention on tumor formation and progression (VIII., XIII). 
In my thesis I presented therapeutic modalities for head and neck tumors in order to 
remove and/ or eliminate tumor cells: minimally invasive endoscopic technique versus 
external approach for early glottic and supraglottic cancer of the larynx. Furthermore 
promising in vitro immunotherapeutical modalities like immunotherapy with bispecific 
antibody and treatment with immune response modifier drugs were introduced that can be 
methods of the future fighting against malignancies. 
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